Do analysts rate CPIX or TXMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer PLYX or TXMD?

Polaryx Therapeutics currently has a consensus price target of $7.67, suggesting a potential upside of 283.33%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Polaryx Therapeutics is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polaryx Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate TXMD or CGTX?

Cognition Therapeutics has a consensus price target of $3.33, suggesting a potential upside of 223.62%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cognition Therapeutics is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Do analysts rate TXMD or VRCA?

Verrica Pharmaceuticals has a consensus target price of $12.67, suggesting a potential upside of 138.99%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Verrica Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Do analysts prefer FBIO or TXMD?

Fortress Biotech currently has a consensus price target of $17.00, suggesting a potential upside of 525.00%. Given Fortress Biotech's stronger consensus rating and higher probable upside, equities analysts plainly believe Fortress Biotech is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortress Biotech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

TherapeuticsMD (TXMD) Competitors

$2.21 -0.03 (-1.34%)

As of 09/4/2026 04:00 PM Eastern

Compare

TXMD vs. CPIX, PLYX, CGTX, VRCA, and FBIO

Should you buy TherapeuticsMD stock or one of its competitors? TherapeuticsMD's main competitors and comparable companies include Cumberland Pharmaceuticals (CPIX), Polaryx Therapeutics (PLYX), Cognition Therapeutics (CGTX), Verrica Pharmaceuticals (VRCA), and Fortress Biotech (FBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does TherapeuticsMD compare to Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TherapeuticsMD has a net margin of -6.64% compared to Cumberland Pharmaceuticals' net margin of -34.40%. TherapeuticsMD's return on equity of -1.09% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%
TherapeuticsMD	-6.64%	-1.09%	-0.78%

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

TherapeuticsMD has lower revenue, but higher earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.28	-$2.84M	-$0.71	N/A
TherapeuticsMD	$3.27M	7.82	-$570K	$0.02	110.50

Cumberland Pharmaceuticals has a beta of 0.13, suggesting that its share price is 87% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

In the previous week, Cumberland Pharmaceuticals had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 1 mentions for Cumberland Pharmaceuticals and 0 mentions for TherapeuticsMD. Cumberland Pharmaceuticals' average media sentiment score of 0.37 beat TherapeuticsMD's score of 0.00 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Cumberland Pharmaceuticals	Neutral
TherapeuticsMD	Neutral

Summary

TherapeuticsMD beats Cumberland Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does TherapeuticsMD compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

TherapeuticsMD has higher revenue and earnings than Polaryx Therapeutics. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A
TherapeuticsMD	$3.27M	7.82	-$570K	$0.02	110.50

Polaryx Therapeutics currently has a consensus price target of $7.67, suggesting a potential upside of 283.33%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Polaryx Therapeutics is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Polaryx Therapeutics has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. Polaryx Therapeutics' return on equity of 0.00% beat TherapeuticsMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
TherapeuticsMD	-6.64%	-1.09%	-0.78%

In the previous week, Polaryx Therapeutics had 3 more articles in the media than TherapeuticsMD. MarketBeat recorded 3 mentions for Polaryx Therapeutics and 0 mentions for TherapeuticsMD. Polaryx Therapeutics' average media sentiment score of 0.25 beat TherapeuticsMD's score of 0.00 indicating that Polaryx Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Polaryx Therapeutics	Neutral
TherapeuticsMD	Neutral

30.7% of TherapeuticsMD shares are owned by institutional investors. 45.8% of Polaryx Therapeutics shares are owned by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Polaryx Therapeutics beats TherapeuticsMD on 10 of the 15 factors compared between the two stocks.

How does TherapeuticsMD compare to Cognition Therapeutics?

TherapeuticsMD (NASDAQ:TXMD) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Cognition Therapeutics has a consensus price target of $3.33, suggesting a potential upside of 223.62%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cognition Therapeutics is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

TherapeuticsMD has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market.

TherapeuticsMD has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.27M	7.82	-$570K	$0.02	110.50
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A

Cognition Therapeutics has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. TherapeuticsMD's return on equity of -1.09% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
Cognition Therapeutics	N/A	-50.17%	-40.22%

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by company insiders. Comparatively, 11.1% of Cognition Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, TherapeuticsMD's average media sentiment score of 0.00 equaled Cognition Therapeutics'average media sentiment score.

Company	Overall Sentiment
TherapeuticsMD	Neutral
Cognition Therapeutics	Neutral

Summary

Cognition Therapeutics beats TherapeuticsMD on 7 of the 13 factors compared between the two stocks.

How does TherapeuticsMD compare to Verrica Pharmaceuticals?

TherapeuticsMD (NASDAQ:TXMD) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

TherapeuticsMD has higher earnings, but lower revenue than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.27M	7.82	-$570K	$0.02	110.50
Verrica Pharmaceuticals	$30.32M	3.00	-$17.89M	-$1.67	N/A

TherapeuticsMD has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

TherapeuticsMD has a net margin of -6.64% compared to Verrica Pharmaceuticals' net margin of -102.84%. TherapeuticsMD's return on equity of -1.09% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%

Verrica Pharmaceuticals has a consensus target price of $12.67, suggesting a potential upside of 138.99%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, TherapeuticsMD's average media sentiment score of 0.00 equaled Verrica Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
TherapeuticsMD	Neutral
Verrica Pharmaceuticals	Neutral

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by insiders. Comparatively, 52.9% of Verrica Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

TherapeuticsMD and Verrica Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does TherapeuticsMD compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Fortress Biotech has higher revenue and earnings than TherapeuticsMD. Fortress Biotech is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.43	$6.82M	$2.64	1.03
TherapeuticsMD	$3.27M	7.82	-$570K	$0.02	110.50

Fortress Biotech currently has a consensus price target of $17.00, suggesting a potential upside of 525.00%. Given Fortress Biotech's stronger consensus rating and higher probable upside, equities analysts plainly believe Fortress Biotech is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Fortress Biotech has a net margin of 163.32% compared to TherapeuticsMD's net margin of -6.64%. Fortress Biotech's return on equity of 83.47% beat TherapeuticsMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
TherapeuticsMD	-6.64%	-1.09%	-0.78%

In the previous week, Fortress Biotech had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 1 mentions for Fortress Biotech and 0 mentions for TherapeuticsMD. Fortress Biotech's average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
Fortress Biotech	Neutral
TherapeuticsMD	Neutral

Fortress Biotech has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

Summary

Fortress Biotech beats TherapeuticsMD on 13 of the 15 factors compared between the two stocks.

Get TherapeuticsMD News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TXMD vs. The Competition

Export

Metric	TherapeuticsMD	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$25.93M	$12.29B	$7.28B	$12.92B
Dividend Yield	N/A	2.59%	2.54%	8.90%
P/E Ratio	110.50	787.21	272.43	25.42
Price / Sales	7.82	793.47	638.12	97.12
Price / Cash	48.01	92.18	77.39	52.28
Price / Book	0.94	12.47	12.85	6.17
Net Income	-$570K	$2.82B	$3.48B	$349.50M
7 Day Performance	-0.45%	3.91%	0.99%	-0.15%
1 Month Performance	6.76%	6.17%	5.49%	1.02%
1 Year Performance	104.63%	9.88%	24.34%	14.50%

TherapeuticsMD Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TXMD TherapeuticsMD	0.9418 of 5 stars	$2.21 -1.3%	N/A	+104.6%	$25.93M	$3.27M	110.50	420	Positive News
CPIX Cumberland Pharmaceuticals	0.7261 of 5 stars	$6.56 -1.9%	N/A	+85.5%	$100.24M	$44.52M	N/A	80	Positive News
PLYX Polaryx Therapeutics	2.7975 of 5 stars	$1.98 -1.5%	$7.67 +287.2%	N/A	$100.19M	N/A	N/A	11
CGTX Cognition Therapeutics	2.0233 of 5 stars	$1.01 -1.9%	$3.33 +230.0%	-60.2%	$97.95M	N/A	N/A	20	Positive News
VRCA Verrica Pharmaceuticals	3.6666 of 5 stars	$5.24 -4.0%	$12.67 +141.7%	+2.7%	$93.80M	$30.32M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TXMD) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TherapeuticsMD (TXMD) Competitors

TXMD vs. CPIX, PLYX, CGTX, VRCA, and FBIO

How does TherapeuticsMD compare to Cumberland Pharmaceuticals?

Summary

How does TherapeuticsMD compare to Polaryx Therapeutics?

Summary

How does TherapeuticsMD compare to Cognition Therapeutics?

Summary

How does TherapeuticsMD compare to Verrica Pharmaceuticals?

Summary

How does TherapeuticsMD compare to Fortress Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD vs. The Competition

TherapeuticsMD Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TherapeuticsMD (TXMD) Competitors

TXMD vs. CPIX, PLYX, CGTX, VRCA, and FBIO

How does TherapeuticsMD compare to Cumberland Pharmaceuticals?

Do analysts rate CPIX or TXMD?

Is CPIX or TXMD more profitable?

Do institutionals & insiders have more ownership in CPIX or TXMD?

Which has better earnings & valuation, CPIX or TXMD?

Which has more risk & volatility, CPIX or TXMD?

Does the media refer more to CPIX or TXMD?

Summary

How does TherapeuticsMD compare to Polaryx Therapeutics?

Which has higher valuation & earnings, PLYX or TXMD?

Do analysts prefer PLYX or TXMD?

Is PLYX or TXMD more profitable?

Does the media prefer PLYX or TXMD?

Do insiders and institutionals hold more shares of PLYX or TXMD?

Summary

How does TherapeuticsMD compare to Cognition Therapeutics?

Do analysts rate TXMD or CGTX?

Which has more volatility and risk, TXMD or CGTX?

Which has stronger earnings & valuation, TXMD or CGTX?

Is TXMD or CGTX more profitable?

Do institutionals and insiders hold more shares of TXMD or CGTX?

Does the media favor TXMD or CGTX?

Summary

How does TherapeuticsMD compare to Verrica Pharmaceuticals?

Which has better valuation & earnings, TXMD or VRCA?

Which has more risk & volatility, TXMD or VRCA?

Is TXMD or VRCA more profitable?

Do analysts rate TXMD or VRCA?

Does the media refer more to TXMD or VRCA?

Do institutionals & insiders hold more shares of TXMD or VRCA?

Summary

How does TherapeuticsMD compare to Fortress Biotech?

Which has better earnings & valuation, FBIO or TXMD?

Do analysts prefer FBIO or TXMD?

Do insiders & institutionals have more ownership in FBIO or TXMD?

Is FBIO or TXMD more profitable?

Does the media favor FBIO or TXMD?

Which has more volatility and risk, FBIO or TXMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD vs. The Competition

TherapeuticsMD Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools